Tavares Pereira João Pedro, Romão Vera, Eulálio Margarida, Jorge Rita, Breda Filipe, Calretas Suzana, Leitão Sara, Eugénio Gisela, Santos Rui, Carvalho Armando
Department of Internal Medicine, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Department of Internal Medicine, Centro Hospiatalar e Universitário de Coimbra, Coimbra, Portugal.
Am J Case Rep. 2016 Feb 1;17:55-9. doi: 10.12659/AJCR.896145.
Sclerosing mesenteritis is an idiopathic inflammatory and fibrotic disease that affects the mesentery. It is a rare disease, with the total number of reported cases in the literature ranging from 122 to 300. It mainly affects men in the sixth decade of life, and its etiology remains unknown. Clinical presentation is variable, but it is frequently asymptomatic. Diagnosis is often made by computed tomography (CT) scan, although biopsy may be needed for confirmation. An association between other diseases (e.g., neoplasms) and sclerosing mesenteritis has been described, but the relationship between the latter and glucose changes is not disclosed in the currently available literature.
Five cases of sclerosing mesenteritis and glucose metabolism disorders (impaired fasting glucose and type 2 diabetes mellitus) were retrospectively collected and analyzed. The mean age was 65 ± 9.3 years, 80% were male, and all patients were white. Three patients were asymptomatic and the other 2 (40%) had non-specific chronic abdominal pain. Blood tests revealed normal inflammatory parameters (mean HbA1c was 6.4% and fasting blood glucose was 140 mg/dL). The diagnosis was made by abdominal CT scan. The 2 symptomatic patients underwent therapy with colchicine 1 mg/day, with clinical improvement. During the mean 43-month follow-up period, there was no symptomatic progression, thereby maintaining the usual benign course of this condition.
Sclerosing mesenteritis has only been described in small series and isolated cases, but its diagnosis is becoming more common due to greater access to diagnostic methods and higher awareness of the disease in the medical community. Furthermore, despite the small sample size, we describe a possible association between glucose metabolism impairment and sclerosing mesenteritis.
硬化性肠系膜膜炎是一种影响肠系膜的特发性炎症和纤维化疾病。它是一种罕见疾病,文献报道的病例总数在122至300例之间。它主要影响60岁左右的男性,其病因仍然不明。临床表现多样,但通常无症状。诊断常通过计算机断层扫描(CT)进行,不过可能需要活检来确诊。已有文献描述了其他疾病(如肿瘤)与硬化性肠系膜膜炎之间的关联,但目前可得文献中未披露后者与血糖变化之间的关系。
回顾性收集并分析了5例硬化性肠系膜膜炎合并糖代谢紊乱(空腹血糖受损和2型糖尿病)的病例。平均年龄为65±9.3岁,80%为男性,所有患者均为白人。3例患者无症状,另外2例(40%)有非特异性慢性腹痛。血液检查显示炎症指标正常(平均糖化血红蛋白为6.4%,空腹血糖为140mg/dL)。诊断通过腹部CT扫描做出。2例有症状的患者接受了每天1mg秋水仙碱的治疗,临床症状有所改善。在平均43个月的随访期内,没有症状进展,从而维持了该病通常的良性病程。
硬化性肠系膜膜炎仅在小系列病例和个别病例中有所描述,但由于诊断方法的可及性提高以及医学界对该疾病的认识增强,其诊断正变得越来越普遍。此外,尽管样本量较小,但我们描述了糖代谢受损与硬化性肠系膜膜炎之间可能存在的关联。